Taylor Hoffman Capital Management LLC Has $4.17 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Taylor Hoffman Capital Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 2.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,808 shares of the company’s stock after acquiring an additional 713 shares during the period. Johnson & Johnson makes up 1.5% of Taylor Hoffman Capital Management LLC’s portfolio, making the stock its 26th biggest position. Taylor Hoffman Capital Management LLC’s holdings in Johnson & Johnson were worth $4,166,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in shares of Johnson & Johnson by 14.8% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 460,969 shares of the company’s stock worth $66,665,000 after purchasing an additional 59,393 shares in the last quarter. Financial Avengers Inc. increased its position in shares of Johnson & Johnson by 2.6% during the 4th quarter. Financial Avengers Inc. now owns 44,623 shares of the company’s stock worth $6,453,000 after purchasing an additional 1,151 shares in the last quarter. CSS LLC IL increased its position in shares of Johnson & Johnson by 20.9% during the 4th quarter. CSS LLC IL now owns 12,627 shares of the company’s stock worth $1,826,000 after purchasing an additional 2,180 shares in the last quarter. First Heartland Consultants Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $1,269,000. Finally, Ames National Corp acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $1,903,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.7%

Johnson & Johnson stock opened at $153.58 on Wednesday. The company’s 50 day simple moving average is $155.87 and its 200 day simple moving average is $153.80. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a market capitalization of $369.52 billion, a price-to-earnings ratio of 23.09, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is presently 57.84%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Stifel Nicolaus lowered their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.